Tags

Type your tag names separated by a space and hit enter

Disease burden and molecular epidemiology of carbapenem-resistant Klebsiella pneumonia infection in a tertiary hospital in China.
Ann Transl Med. 2020 May; 8(9):605.AT

Abstract

Background

Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become an urgent global public health issue, but its distribution has obvious regional differences. The purpose of this study was to investigate the patient-based disease burden and molecular epidemiology of CRKP infections in a tertiary hospital in northern Jiangsu Province in China.

Methods

A retrospective, epidemiological survey of CRKP infections in our hospital from January to December 2016 was conducted to collect clinical and epidemiologic data. Non-duplicated clinical CRKP isolates were collected for the resistance-associated genes and clonal correlation analysis by PCR, sequencing and multilocus sequence typing (MLST).

Results

252 CRKP infection cases were collected, and the annual CRKP infection incidence of the hospital during 2016 was 14.64 per 10,000 hospital discharges (252/172,112*10,000) and 13.78 per 100,000 patient days (252/1,829,190*100,000). The patient-based disease burden concentrated on antimicrobial exposure history (133/224, 59.37%)-the most dominant STs. KPC-2 (120/128, 93.8%) was the predominant carbapenemase and ST11 (98/128, 76.5%) was the dominant STs. One isolate was detected with harboring blaKPC-2 and blaMCR-1 simultaneously.

Conclusions

Patient-based disease burden and KPC-2-producing ST11 Klebsiella pneumonia caused in higher CRKP incidence in the hospital. The emergence of CRKP with blaKPC-2 and blaMCR-1 should be of concern.

Authors+Show Affiliations

School of Medicine, Shandong University, Jinan 250012, China. Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.Department of Hospital-Acquired Infection Control, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.Medical Technology School, Xuzhou Medical University, Xuzhou 221004, China.Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. Medical Technology School, Xuzhou Medical University, Xuzhou 221004, China.Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. Medical Technology School, Xuzhou Medical University, Xuzhou 221004, China.Department of Clinical Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32566631

Citation

Kang, Haiquan, et al. "Disease Burden and Molecular Epidemiology of Carbapenem-resistant Klebsiella Pneumonia Infection in a Tertiary Hospital in China." Annals of Translational Medicine, vol. 8, no. 9, 2020, p. 605.
Kang H, Zheng W, Kong Z, et al. Disease burden and molecular epidemiology of carbapenem-resistant Klebsiella pneumonia infection in a tertiary hospital in China. Ann Transl Med. 2020;8(9):605.
Kang, H., Zheng, W., Kong, Z., Jiang, F., Gu, B., Ma, P., & Ma, X. (2020). Disease burden and molecular epidemiology of carbapenem-resistant Klebsiella pneumonia infection in a tertiary hospital in China. Annals of Translational Medicine, 8(9), 605. https://doi.org/10.21037/atm.2020.03.122
Kang H, et al. Disease Burden and Molecular Epidemiology of Carbapenem-resistant Klebsiella Pneumonia Infection in a Tertiary Hospital in China. Ann Transl Med. 2020;8(9):605. PubMed PMID: 32566631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Disease burden and molecular epidemiology of carbapenem-resistant Klebsiella pneumonia infection in a tertiary hospital in China. AU - Kang,Haiquan, AU - Zheng,Wei, AU - Kong,Ziyan, AU - Jiang,Fei, AU - Gu,Bing, AU - Ma,Ping, AU - Ma,Xiaoling, PY - 2020/6/23/entrez PY - 2020/6/23/pubmed PY - 2020/6/23/medline KW - Carbapenem-resistant Klebsiella pneumonia KW - ST11 KW - infection SP - 605 EP - 605 JF - Annals of translational medicine JO - Ann Transl Med VL - 8 IS - 9 N2 - Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become an urgent global public health issue, but its distribution has obvious regional differences. The purpose of this study was to investigate the patient-based disease burden and molecular epidemiology of CRKP infections in a tertiary hospital in northern Jiangsu Province in China. Methods: A retrospective, epidemiological survey of CRKP infections in our hospital from January to December 2016 was conducted to collect clinical and epidemiologic data. Non-duplicated clinical CRKP isolates were collected for the resistance-associated genes and clonal correlation analysis by PCR, sequencing and multilocus sequence typing (MLST). Results: 252 CRKP infection cases were collected, and the annual CRKP infection incidence of the hospital during 2016 was 14.64 per 10,000 hospital discharges (252/172,112*10,000) and 13.78 per 100,000 patient days (252/1,829,190*100,000). The patient-based disease burden concentrated on antimicrobial exposure history (133/224, 59.37%)-the most dominant STs. KPC-2 (120/128, 93.8%) was the predominant carbapenemase and ST11 (98/128, 76.5%) was the dominant STs. One isolate was detected with harboring blaKPC-2 and blaMCR-1 simultaneously. Conclusions: Patient-based disease burden and KPC-2-producing ST11 Klebsiella pneumonia caused in higher CRKP incidence in the hospital. The emergence of CRKP with blaKPC-2 and blaMCR-1 should be of concern. SN - 2305-5839 UR - https://www.unboundmedicine.com/medline/citation/32566631/Disease_burden_and_molecular_epidemiology_of_carbapenem_resistant_Klebsiella_pneumonia_infection_in_a_tertiary_hospital_in_China_ L2 - https://doi.org/10.21037/atm.2020.03.122 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.